Maria Stella Graziani

Deputy Director
Martina Zaninotto

Associate Editors
Ferruccio Ceriotti
Davide Giavarina
Bruna Lo Sasso
Giampaolo Merlini
Martina Montagnana
Andrea Mosca
Paola Pezzati
Rossella Tomaiuolo
Matteo Vidali

International Advisory Board Khosrow Adeli Canada
Sergio Bernardini Italy
Marcello Ciaccio Italy
Eleftherios Diamandis Canada
Philippe Gillery France
Kjell Grankvist Sweden
Hans Jacobs The Netherlands
Eric Kilpatrick UK
Magdalena Krintus Poland
Giuseppe Lippi Italy
☩Howard Morris Australia
Mario Plebani Italy
Sverre Sandberg Norway
Ana-Maria Simundic Croatia
☩Jill Tate Australia
Tommaso Trenti Italy
Cas Weykamp The Netherlands
Maria Willrich USA
Paul Yip Canada

Biomedia srl
Via L. Temolo 4, 20126 Milano

Responsible Editor
Giuseppe Agosta

Editorial Secretary
Arianna Lucini Paioni
Biomedia srl
Via L. Temolo 4, 20126 Milano
Tel. 0245498282
email: biochimica.clinica@sibioc.it

Area soci
Non possiedi o non ricordi la password!
Clicca qui

BC: Articoli scritti da A. Perandini

Determinazione dell’ormone anti-mulleriano per la valutazione della riserva ovarica in pazienti dopo trattamento chemioterapico
Utility of anti-mullerian hormone for the evaluation of fertility preservation in female patients after chemotherapy
<p>The new advances in the treatment have greatly increased the life expectancy of premenopausal women with&nbsp;hematological malignancies. The susceptibility of their ovarian reserve to chemotherapy is however highly variable. The&nbsp;anti-mullerian hormone (AMH) is one of the most sensitive markers of ovarian reserve and fertility preservation. In this study,&nbsp;antral follicle counts (AFC), serum AMH, follicle stimulating hormone (FSH) and inhibin B were assayed in female patients&nbsp;treated for lymphoma and hematological disease to characterize the evolution of fertility preservation. 63 consecutive&nbsp;women (48 with Hodgkin&#39;s lymphoma, 9 non-Hodgkin&#39;s lymphoma, 6 acute myeloid leukemia) were eligible for enrolment.&nbsp;All patients [median age, 31 years (range: 17-40)] were in complete remission with a median follow-up time of 9.0 years&nbsp;after therapy. 64 healthy controls were also evaluated [median age, 31 years (range: 20-42)]. Participants had a baseline&nbsp;blood drawing during the early follicular phase of the menstrual cycle. A significant difference in AFC (9.8 vs. 16.0,&nbsp;P=0.0001), AMH (2.02 &mu;g/L vs. 2.97 &mu;g/L, P=0.02), FSH (16.9 U/L vs. 8.1 U/L, P=0.03) and inhibin B (33.7 ng/L vs. 69.4&nbsp;ng/L, P &lt;0.005) was observed between patients and controls. The ROC curve analysis comparing AMH and FSH&nbsp;concentrations of patients (at the same AFC cut-off point of 8) revealed that AMH had a better area under the curve (0.904)&nbsp;than FSH (0.678) (P=0.0013). The ovarian reserve is reduced in female patients affected by hematological malignancies&nbsp;after chemotheraphy. AMH is the most reliable serum marker of fertility preservation in these subjects.</p>
Biochimica Clinica ; 38(5) 374-377
Contributi scientifici - Scientific Papers